Hepatic Encephalopathy clinical trials at University of California Health

• Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy

  open to eligible people ages 18 years and up

  The purpose of the study is to evaluate the safety of Rifaximin or placebo in subjects with severe hepatic impairment and Hepatic Encephalopathy.

  at UCSD

• TReatment for ImmUne Mediated PathopHysiology

  Sorry, not yet accepting patients

  TReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three arm, randomized, controlled trial of immunosuppressive therapy for children with acute liver failure. The study will determine if suppressing inflammatory responses with either corticosteroids or equine anti-thymocyte globulin therapy improves survival for children with this rare, life-threatening condition.

  at UCSF

Last updated: April 23, 2021